Tocimab 200 mg/10 ml (IV Infusion)
10 ml vial: ৳ 20,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Tocilizumab |
| Company | Healthcare pharmaceuticals ltd |
Title
- Tocilizumab (Tocimab)
Categories
- Medicine
- Immunosuppressant
- Biologic Drug
- Treatments for Rheumatoid Arthritis
- Therapeutic Class: Drugs used for Rheumatoid Arthritis
Description
- Recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin IgG1K subclass
- Binds to both soluble and membrane-bound IL-6 receptors
- Inhibits IL-6-mediated signaling
- Indicated for Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Systemic Juvenile Idiopathic Arthritis (SJIA), COVID-19, Cytokine Release Syndrome (CRS), Giant Cell Arteritis (GCA), Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
- Dosage administered by intravenous infusion or subcutaneous injection
- Exercise caution when coadministering with CYP3A4 substrate drugs
- Contraindicated in patients with known hypersensitivity to Tocilizumab
- Most common adverse reactions include upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions
- Pregnancy & Lactation: May cause fetal harm, should be used during pregnancy only if potential benefit justifies potential risk
- Precautions & Warnings: Serious Infections, Tuberculosis, Gastrointestinal Perforation, Hepatotoxicity, Laboratory Monitoring, Hypersensitivity reactions, Live Vaccines, Avoid using with biological DMARDs
- Use in Special Populations: Pediatric Use, Geriatric Use, Hepatic Impairment, Renal Impairment
- Storage Conditions: Store at 2°C to 8°C, do not freeze